Lymecycline
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Lymecycline
| |
| Systematic (IUPAC) name | |
| 2-(amino-hydroxy-methylidene)- 7-chloro-4-dimethylamino- 6,10,11,12a- tetrahydroxy-6-
methyl- 4,4a,5,5a-tetrahydrotetracene-1 ,3,12-trione | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | CH23N2O8 |
| Mol. mass | 478.879 |
| Pharmacokinetic data | |
| Bioavailability | 100% (oral) |
| Metabolism | ? |
| Half life | ? |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? (Aust) |
| Legal status |
Schedule 4 (Aust) |
| Routes | oral |
|
WikiDoc Resources for Lymecycline | |
|
Articles | |
|---|---|
|
Most recent articles on Lymecycline Most cited articles on Lymecycline | |
|
Media | |
|
Powerpoint slides on Lymecycline | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Lymecycline at Clinical Trials.gov Clinical Trials on Lymecycline at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Lymecycline
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Lymecycline Discussion groups on Lymecycline Patient Handouts on Lymecycline Directions to Hospitals Treating Lymecycline Risk calculators and risk factors for Lymecycline
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Lymecycline | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Lymecycline is a tetracycline broad-spectrum antibiotic marketed by the pharmeceutical company Galderma[2]. It is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by the "active transport" process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed.
The greater absorption of Lymecycline allows for lower dosages to be used; the standard dose of 408 mg is equivalent to 300 mg tetracycline base, and in its action to 500 mg tetracycline hydrochloride. Lymecycline, unlike tetracycline hydrochloride, is soluble at all physiological pH values.
History
Lymecycline was released onto the pharmaceutical market in 1963.
Indications
Lymecycline, like other Tetracyclines, is used to treat a range of infections (see Tetracycline antibiotics group). Its better absorption profile makes it preferable to tetracycline for moderately severe acne and typically prescribed for 8 weeks at a time, but alternatives should be sought if no improvement occurs by 3 months.
Dosage
The standard dose is 408mg (one capsule) twelve hourly by mouth. In particularly severe infections this dose may be increased to 1.224-1.632mg (three or four capsules) daily.
The 408mg once daily dosage for acne aids good drug compliance.
Formulation
Capsules containing 408mg of Lymecycline (brand name Tetrlysal 300).
References
- ^ New Zealand Datasheet August 2003
- ^ British National Formulary 45 March 2003
See also
Antibacterials for systemic use: tetracycline antibiotics (J01A) | |
|---|---|
| Tetracyclines | Chlortetracycline • Clomocycline • Demeclocycline • Doxycycline • Lymecycline • Metacycline • Minocycline • Oxytetracycline • Penimepicycline • Rolitetracycline • Tetracycline |
| Glycylcyclines | Tigecycline |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
